HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies

Blood

Volumn 124, Issue 8, 2014, Pages 1266-1276

  Fernandez, Christian A ^a   Smith, Colton ^a   Yang, Wenjian ^a   Daté, Mihir ^a   Bashford, Donald ^a   Larsen, Eric ^b   Bowman, W Paul ^c   Liu, Chengcheng ^a   Ramsey, Laura B ^a   Chang, Tamara ^a   Turner, Victoria ^a   Loh, Mignon L ^d   Raetz, Elizabeth A ^e   Winick, Naomi J ^f   Hunger, Stephen P ^g   Carroll, William L ^e   Onengut Gumuscu, Suna ^h   Chen, Wei Min ^h   Concannon, Patrick ⁱ   Rich, Stephen S ^h   Scheet, Paul ^j   Jeha, Sima ^a   Pui, Ching Hon ^a   Evans, William E ^a   Devidas, Meenakshi ^k   Relling, Mary V ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Maine Children's Cancer Program Scarborough   (United States)

^c Cook Children's Medical Center ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIBODY; ASPARAGINASE; EPITOPE; HLA ANTIGEN CLASS 2; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; ANTINEOPLASTIC AGENT; HLA DRB1*07 ANTIGEN; HLA-DRB1*07 ANTIGEN;

ADOLESCENT; ADULT; ALLELE; ALLERGIC REACTION; AMINO ACID SEQUENCE; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CHILD; COHORT ANALYSIS; CONSENSUS SEQUENCE; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; ESCHERICHIA COLI; FEMALE; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; RISK FACTOR; BLOOD; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; GENETICS; IMMUNOLOGY; INFANT; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ALLELES; ANTIBODIES; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; EPITOPES; FEMALE; HLA-DRB1 CHAINS; HUMANS; INFANT; LEUKEMIA; MALE; RISK FACTORS;

EID: 84907363522     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-563742     Document Type: Article

References (82)

1. Asselin BL, Ryan D, Frantz CN, et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 1989;49(15):4363-4368. (Pubitemid 19207288)
2. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621-629. (Pubitemid 129735360)
3. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer. 1970;25(2):253-278.
4. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22(9):1665-1679.
5. Bowman WP, Larsen EL, Devidas M, et al. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr Blood Cancer. 2011;57(4):569-577.
6. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-1218. (Pubitemid 32183741)
7. Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol. 2007;120(3):506-517.
8. Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012;26(11):2303-2309.
9. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8(3):186-195. (Pubitemid 351712643)
10. Reveille JD. The genetic basis of autoantibody production. Autoimmun Rev. 2006;5(6):389-398. (Pubitemid 44143031)
11. National Cancer Institute. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. June 1, 1999. http://ctep.cancer.gov/reporting/ ctc.html; 1999.
12. Wang B, Hak LJ, Relling MV, Pui CH, Woo MH, Storm MC. ELISA to evaluate plasma antiasparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods. 2000;239(1-2):75-83. (Pubitemid 30256020)
13. Treviño LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1001-1005.
14. Yang JJ, Cheng C, Devidas M, et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet. 2011;43(3):237-241.
15. Pereyra F, Jia X, McLaren PJ, et al; International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330(6010):1551-1557.
16. Robinson J, Waller MJ, Fail SC, et al. The IMGT/HLA database. Nucleic Acids Res. 2009; 37(Database issue):D1013-D1017.
17. Zhang XC, Li SS, Wang H, Hansen JA, Zhao LP. Empirical evaluations of analytical issues arising from predicting HLA alleles using multiple SNPs. BMC Genet. 2011;12:39.
18. Dilthey A, Leslie S, Moutsianas L, et al. Multipopulation classical HLA type imputation. PLOS Comput Biol. 2013;9(2):e1002877.
19. Tekola Ayele F, Hailu E, Finan C, et al. Prediction of HLA class II alleles using SNPs in an African population [published correction appears in PLos ONE. 2012;7(7) doi/10.1371/annotation/3529a6a2-4ba2-47dc-929e-399d441b0afa] . PLoS ONE. 2012;7(6):e40206.
20. Jia X, Han B, Onengut-Gumuscu S, et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS ONE. 2013;8(6):e64683.
21. Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am J Hum Genet. 2009;84(2):210-223.
22. Spraggs CF, Budde LR, Briley LP, et al. HLA-DQA1*02:01 is a major risk factor for lapatinibinduced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29(6):667-673.
23. Simon MR, Jan M, Yee J, et al. Tryptase is not cleared by the kidneys into the urine. Int Arch Allergy Immunol. 2010;152(1):28-31.
24. Vita R, Zarebski L, Greenbaum JA, et al. The immune epitope database 2.0. Nucleic Acids Res. 2010;38(Database issue):D854-D862.
25. Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLOS Comput Biol. 2008;4(4):e1000048.
26. Wang P, Sidney J, Kim Y, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 2010;11:568.
27. Laroche D, Vergnaud MC, Sillard B, Soufarapis H, Bricard H. Biochemical markers of anaphylactoid reactions to drugs. Comparison of plasma histamine and tryptase. Anesthesiology. 1991;75(6):945-949.
28. Schleimer RP, Gillespie E, Daiuta R, Lichtenstein LM. Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. II. Interaction with other stimuli. J Immunol. 1982;128(1):136-140. (Pubitemid 12207431)
29. Peitsch MC. Protein modeling by e-mail. Nat Bio-Technol. 1995;13(7):658-660.
30. Günther S, Schlundt A, Sticht J, et al. Bidirectional binding of invariant chain peptides to an MHC class II molecule. Proc Natl Acad Sci USA. 2010;107(51):22219-22224.
31. Pierce BG, Hourai Y, Weng Z. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS ONE. 2011;6(9):e24657.
32. Raveh B, London N, Schueler-Furman O. Subangstrom modeling of complexes between flexible peptides and globular proteins. Proteins. 2010;78(9):2029-2040.
33. Case D, Darden TA, Cheatham TE, et al. Amber 12. San Francisco: University of California; 2012.
34. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins. 2006;65(3):712-725. (Pubitemid 44583220)
35. Wang W, Donini O, Reyes CM, Kollman PA. Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. Annu Rev Biophys Biomol Struct. 2001;30:211-243. (Pubitemid 32566163)
36. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11(9):1780-1786. (Pubitemid 23277332)
37. Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32(7):554-563.
38. Avramis VI, Avramis EV, Hunter W, Long MC. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res. 2009;29(1):299-302.
39. Ebeid EN, Kamel MM, Ali BA. Detection of antiasparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma. J Egypt Natl Canc Inst. 2008;20(2):127-133.
40. Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54(2):199-205.
41. Woo MH, Hak LJ, Storm MC, et al. Antiasparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia. 1998;12(10):1527-1533. (Pubitemid 28470435)
42. Willer A, Gerss J, König T, et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood. 2011;118(22):5774-5782.
43. Panosyan EH, Seibel NL, Martin-Aragon S, et al; Children's Cancer Group Study CCG-1961. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217-226. (Pubitemid 38500969)
44. Albertsen BK, Schrøder H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol. 2002;38(5):310-316. (Pubitemid 34493110)
45. Eden OB, Shaw MP, Lilleyman JS, Richards S. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol. 1990;18(6):497-502.
46. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18(7):1525-1532. (Pubitemid 30205399)
47. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer. 1982;49(7):1378-1383. (Pubitemid 12143059)
48. Chen SH, Pei D, Yang W, et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. 2010;88(2):191-196.
49. Trowsdale J. The MHC, disease and selection. Immunol Lett. 2011;137(1-2):1-8.
50. Price P, Witt C, Allcock R, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev. 1999;167:257-274. (Pubitemid 29178987)
51. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med. 1989;169(1):345-350. (Pubitemid 19035567)
52. Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44(3):291-296.
53. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med. 1978;298(16):869-871. (Pubitemid 8330170)
54. Erlich HA, Valdes AM, McDevitt SL, et al; Type 1 Diabetes Genetics Consortium (T1DGC). Next generation sequencing reveals the association of DRB3*02:02 with type 1 diabetes. Diabetes. 2013;62(7):2618-2622.
55. Davies JL, Kawaguchi Y, Bennett ST, et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature. 1994;371(6493):130-136. (Pubitemid 24284009)
56. Oksenberg JR, Barcellos LF. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun. 2005;6(5):375-387. (Pubitemid 43090513)
57. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727-732. (Pubitemid 34215071)
58. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121-1122. (Pubitemid 34270738)
59. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
60. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102(11):4134-4139.
61. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19(9):704-709.
62. Kaniwa N, Saito Y, Aihara M, et al; JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9(11):1617-1622.
63. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis [published correction appears in Am J Hum Genet. 2008;83(4):541]. Am J Hum Genet. 2008;83(2):219-227.
64. Weber F, Cepok S, Wolf C, et al. Singlenucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-b therapy in multiple sclerosis patients. Pharmacogenomics J. 2012;12(3):238-245.
65. Vigneault F, Woods M, Buzon MJ, et al. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers. J Virol. 2011;85(6):3015-3019.
66. Pereyra F, Jia X, McLaren PJ, et al; International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330(6010):1551-1557.
67. Foo JN, Smedby KE, Akers NK, et al. Coding variants at hexa-allelic amino acid 13 of HLA-DRB1 explain independent SNP associations with follicular lymphoma risk. Am J Hum Genet. 2013;93(1):167-172.
68. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134-1143.
69. de Bakker PI, Raychaudhuri S. Interrogating the major histocompatibility complex with highthroughput genomics. Hum Mol Genet. 2012; 21(R1):R29-R36.
70. Foley PJ, McGrath DS, Puscinska E, et al. Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis. Am J Respir Cell Mol Biol. 2001;25(3):272-277. (Pubitemid 32918907)
71. Ramagopalan SV, McMahon R, Dyment DA, Sadovnick AD, Ebers GC, Wittkowski KM. An extension to a statistical approach for family based association studies provides insights into genetic risk factors for multiple sclerosis in the HLA-DRB1 gene. BMC Med Genet. 2009;10:10.
72. Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006;15(18):2813-2824. (Pubitemid 44400408)
73. Jee SH, Tsai TF, Tsai WL, Liaw SH, Chang CH, Hu CY. HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population. Br J Dermatol. 1998;139(6):978-983. (Pubitemid 29010533)
74. Shindo Y, Inoko H, Yamamoto T, Ohno S. HLADRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994;78(3):223-226. (Pubitemid 24070634)
75. Umemura T, Joshita S, Ichijo T, et al; Shinshu PBC Study Group. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology. 2012;55(2):506-511.
76. Ban Y, Davies TF, Greenberg DA, et al. Arginine at position 74 of the HLA-DR beta1 chain is associated with Graves' disease. Genes Immun. 2004;5(3):203-208. (Pubitemid 38967653)
77. Simmonds MJ, Howson JM, Heward JM, et al. Regression mapping of association between the human leukocyte antigen region and Graves disease. Am J Hum Genet. 2005;76(1):157-163. (Pubitemid 40023775)
78. Menconi F, Osman R, Monti MC, Greenberg DA, Concepcion ES, Tomer Y. Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis. Proc Natl Acad Sci USA. 2010;107(39):16899-16903.
79. Chevalier MF, Jülg B, Pyo A, et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol. 2011;85(2):733-741.
80. Sette A, Peters B. Immune epitope mapping in the post-genomic era: lessons for vaccine development. Curr Opin Immunol. 2007;19(1):106-110. (Pubitemid 46073693)
81. Yanover C, Jain N, Pierce G, Howard TE, Sauna ZE. Pharmacogenetics and the immunogenicity of protein therapeutics. Nat Biotechnol. 2011;29(10):870-873.
82. Cantor JR, Yoo TH, Dixit A, Iverson BL, Forsthuber TG, Georgiou G. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci USA. 2011;108(4):1272-1277.